Bayer switches Astepro Allergy to OTC status in US

18 June 2021 - Deborah Wilkes


The US Food and Drug Administration (FDA) has approved the switch of Astepro (azelastine hydrochloride 0.15%) from prescription-to-OTC status. Bayer said its Astepro Allergy Nasal Spray would be available at national mass retail locations in the first quarter of 2022.

Click tags below for more information on topics:

Bayer Consumer Health

Annual Subscription Holder?

Sign in to continue reading.

Sign In

Back to Industry News

Share this page: